Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Azacitidine
Related studies linked through entity extraction aliases.
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
- Status
- COMPLETED
- Phase
- PHASE3
Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
- Status
- COMPLETED
- Phase
- PHASE1
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65
- Status
- TERMINATED
- Phase
- PHASE2
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
- Status
- TERMINATED
- Phase
- PHASE1
Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)
- Status
- TERMINATED
- Phase
- PHASE3
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
- Status
- TERMINATED
- Phase
- PHASE2
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)
- Status
- TERMINATED
- Phase
- PHASE2
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
- Status
- COMPLETED
- Phase
- PHASE2